West Pharmaceutical Services, Inc. (WST) Stock Price: $350.85+4.29 (+1.24%)
At close: Jun 26, 2026, 4:00 PM ET
The closing share price for West Pharmaceutical Services, Inc. (WST) stock was $350.85 for Friday, June 26, 2026, up 1.24% on the day.
Longer view (total return, dividends reinvested): past 12 months +60.8% · 3-year avg -1.0%/yr · 5-year avg -0.3%/yr
WST Price Chart
WST is featured in
WST Key Metrics
See All MetricsLAST CLOSE PRICE
$350.85
52-WEEK RANGE
$206.80 - $352.31
BETA
1.18
% FROM 52W HIGH
-0.41%
MARKET CAP
$24.79B
DIVIDEND YIELD
0.25%
PE RATIO
trailing TTM
46.84
PE RATIO (FWD)
next-FY estimate
36.63
P/B RATIO
8.49
DEBT / EQUITY
0.13
REVENUE TTM
$3.22B
NET INCOME TTM
$542.70M
NET PROFIT MARGIN TTM
16.85%
TTM TOTAL RETURN
+60.79%
3Y TOTAL RETURN
-1.04%
5Y TOTAL RETURN
-0.26%
WST Revenue by Segment
How WST’s revenue breaks down across its reported segments in the latest reported fiscal year.
By product / business (FY 2025)
- Proprietary Products$2.49B81.1%
- Contract Manufactured Products$582.00M18.9%
By geography (FY 2025)
- United States$1.33B43.3%
- Other Europe Countries$451.00M14.7%
- Germany$380.30M12.4%
- Other Countries$353.30M11.5%
- Ireland$333.30M10.8%
- France$226.60M7.4%
WST Earnings Preview
Next Earnings Date
Jul 23, 2026
26 days away
EPS Estimate
2.08
Revenue Est.
$838.32M
Last Quarter Results
EPS
$2.13
vs Estimate
$1.68
Revenue
$844.90M
vs Estimate
$780.31M
WST Analyst Ratings
Consensus Rating
Based on 14 analysts
Average Price Target
$358.79
+2.3% upside
Low
$310.00
Current
$350.85
High
$400.00
WST Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $2.21 | $2.24 | $2.28 | 3 |
| Q2 2027 | $2.25 | $2.29 | $2.33 | 5 |
| Q3 2027 | $2.38 | $2.42 | $2.46 | 3 |
| Q4 2027 | $2.52 | $2.56 | $2.60 | 6 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $9.32 | $9.58 | $9.83 | 9 |
| FY 2028 | $10.30 | $10.87 | $11.76 | 3 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $850.83M | $861.42M | $871.58M | 4 |
| Q2 2027 | $856.82M | $867.48M | $877.72M | 6 |
| Q3 2027 | $868.92M | $879.73M | $890.11M | 4 |
| Q4 2027 | $875.57M | $886.46M | $896.92M | 7 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $3.46B | $3.53B | $3.60B | 11 |
| FY 2028 | $3.76B | $3.77B | $3.78B | 8 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareWST Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1WST | $24.79B | $350.85 | +1.24% | +60.79% | -0.26% | +17.45% | — |
| 2WAT | $24.41B | $374.41 | -0.66% | +5.50% | +2.08% | +10.69% | vs WST |
| 3MTD | $25.44B | $1243.42 | +3.34% | +5.48% | -1.42% | +13.28% | vs WST |
| 4MRNA | $26.35B | $59.75 | -1.11% | +145.07% | -21.05% | N/A | vs WST |
| 5DGX | $23.08B | $206.24 | +1.54% | +19.90% | +12.14% | +12.40% | vs WST |
| 6BNTX | $23.07B | $91.22 | +1.36% | -14.07% | -16.66% | N/A | vs WST |
WST Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green